You are here:

Category: 2.12 Lipid-regulating drugs

Name SMC ID No Manufacturer Status Sub. Type
 
lomitapide (Lojuxta) 956/14 Not Recommended Non submission
evolocumab (Repatha) 1148/16 Amgen Ltd Not Recommended Full submission
evolocumab (Repatha) 1148/16 Amgen Ltd Restricted Resubmission
rosuvastatin (Crestor) 725/11 AstraZeneca UK Ltd Not Recommended Full submission
rosuvastatin (Crestor®) 45/03 AstraZeneca UK Ltd Accepted Full submission
colesevelam (Cholestagel) 690/11 Genzyme Therapeutics Ltd Not Recommended Non submission
Nicotinic acid modified release tablet (Niaspan®) 93/04 Merck Serono Ltd Not Recommended Resubmission
Nicotinic acid modified release tablets (Niaspan®) 93/04 Merck Serono Ltd Not Recommended Full submission
Nicotonic acid modified release tabs (Niaspan®) 93/04 Merck Serono Ltd Not Recommended Resubmission
nicotinic acid/laropiprant (Tredaptive) 614/10 MSD Suspended Full submission
ezetimibe (Ezetrol) 61/03 MSD/Schering Plough Restricted Full submission
ezetimibe/simvastatin (Inegy) 182/05 MSD/Schering Plough Restricted Abbreviated Submission
Fluvastatin (Lescol) 76/04 Novartis Pharmaceuticals UK Ltd Restricted Full submission
Atorvastatin (Lipitor®) 202/05 Pfizer Ltd Restricted Abbreviated Submission
atorvastatin (Lipitor) 766/12 Pfizer Ltd Accepted Abbreviated Submission
alirocumab (Praluent) 1147/16 Sanofi-Aventis Restricted Full submission

Back